Reducing Alcohol Use Among Patients with Hepatitis C

A Giannopoulos1, J C Elliott1, N Viscaino1

  • 1Molloy University1000 Hempstead Avenue, Rockville CentreNY11570.

Substance Use & Misuse
|January 16, 2026
PubMed

Insights

Psychosocial interventions effectively reduce alcohol consumption in individuals with chronic Hepatitis C Virus (HCV) and HIV/HCV co-infection. These interventions improve abstinence rates and engagement in alcohol treatment, benefiting overall health.

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Addiction Medicine

Background:

  • Heavy alcohol use poses significant risks for individuals with chronic Hepatitis C Virus (HCV) infection.
  • Co-infection with human immunodeficiency virus (HIV) and HCV exacerbates these risks, potentially leading to severe liver damage and mortality.
  • These populations have historically received insufficient clinical attention regarding alcohol use management.

Purpose of the Study:

  • To systematically review and synthesize existing literature on alcohol interventions for individuals with chronic HCV.
  • To specifically examine interventions tailored for the HIV/HCV co-infected population.
  • To build upon and update previous reviews on this topic.

Main Methods:

  • A comprehensive literature search was conducted to identify relevant studies.
  • Included studies evaluated the efficacy of drinking reduction interventions.
  • Studies focused on populations with chronic HCV and those with HIV/HCV co-infection.

Main Results:

  • Seven studies met the inclusion criteria: four for HCV and three for HIV/HCV co-infection.
  • Participants showed significant positive responses to interventions.
  • Key outcomes included increased abstinence rates, reduced alcohol consumption, fewer heavy drinking days, and enhanced treatment engagement.

Conclusions:

  • Psychosocial interventions show promise in reducing alcohol use among individuals with chronic HCV and HIV/HCV co-infection.
  • Successfully reducing alcohol intake is a critical behavioral change with positive implications for patient health.
  • Further research and clinical attention are warranted for these vulnerable populations.
Abstract

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
257
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
215
Alcohols from Carbonyl Compounds: Reduction02:23

Alcohols from Carbonyl Compounds: Reduction

Reduction is a simple strategy to convert a carbonyl group to a hydroxyl group. The three major pathways to reduce carbonyls to alcohols are catalytic hydrogenation, hydride reduction, and borane reduction.
Catalytic hydrogenation is similar to the reduction of an alkene or alkyne by adding H2 across the pi bond in the presence of transition metal catalysts like Raney Ni, Pd–C, Pt, or Ru. Aldehydes and ketones can be reduced by this method, often under mild to moderate heat (25–100°C) and...
12.1K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
185
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
322
CNS Depressants: Alcohol and Nicotine01:27

CNS Depressants: Alcohol and Nicotine

Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
1.0K